Invivo Therapeutics Stock Price, News & Analysis (NASDAQ:NVIV)

$0.47 +0.01 (+2.17 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$0.47
Today's Range$0.45 - $0.50
52-Week Range$0.45 - $4.55
Volume254,887 shs
Average Volume289,402 shs
Market Capitalization$17.82 million
P/E Ratio-0.55
Dividend YieldN/A
Beta2.71

About Invivo Therapeutics (NASDAQ:NVIV)

Invivo Therapeutics logoInVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.

Receive NVIV News and Ratings via Email

Sign-up to receive the latest news and ratings for NVIV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NVIV
CUSIPN/A
Phone617-863-5500

Debt

Debt-to-Equity Ratio0.04%
Current Ratio5.06%
Quick Ratio5.06%

Price-To-Earnings

Trailing P/E Ratio-0.553287608381078
Forward P/E Ratio-0.58
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.90 per share
Price / Book0.52

Profitability

Trailing EPS($0.85)
Net Income$-23,430,000.00
Net MarginsN/A
Return on Equity-134.23%
Return on Assets-109.16%

Miscellaneous

Employees37
Outstanding Shares34,280,000

Invivo Therapeutics (NASDAQ:NVIV) Frequently Asked Questions

What is Invivo Therapeutics' stock symbol?

Invivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."

How were Invivo Therapeutics' earnings last quarter?

Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) posted its quarterly earnings data on Monday, October, 30th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.22) by $0.06. View Invivo Therapeutics' Earnings History.

When will Invivo Therapeutics make its next earnings announcement?

Invivo Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March, 9th 2018. View Earnings Estimates for Invivo Therapeutics.

Where is Invivo Therapeutics' stock going? Where will Invivo Therapeutics' stock price be in 2018?

1 Wall Street analysts have issued 12 month price objectives for Invivo Therapeutics' shares. Their forecasts range from $6.00 to $6.00. On average, they expect Invivo Therapeutics' share price to reach $6.00 in the next twelve months. View Analyst Ratings for Invivo Therapeutics.

Are investors shorting Invivo Therapeutics?

Invivo Therapeutics saw a decrease in short interest in the month of January. As of January 12th, there was short interest totalling 723,191 shares, a decrease of 22.9% from the December 29th total of 937,661 shares. Based on an average daily trading volume, of 321,854 shares, the short-interest ratio is presently 2.2 days. Approximately 2.2% of the company's stock are short sold.

Who are some of Invivo Therapeutics' key competitors?

Who are Invivo Therapeutics' key executives?

Invivo Therapeutics' management team includes the folowing people:

  • Ann Merrifield, Chairman of the Board (Age 66)
  • Richard Toselli M.D., President, Acting Chief Executive Officer and Chief Medical Officer, Director (Age 60)
  • Christopher McNulty, Principal Financial Officer and Principal Accounting Officer (Age 40)
  • Melanie Morel-Ferris, Senior Director, Finance and Controller (Age 36)
  • Tamara L. Joseph J.D., Senior Vice President, Chief Compliance Officer, General Counsel (Age 52)
  • Pamela J. Stahl, Chief Commercial Officer (Age 48)
  • Jeffrey S. Hatfield, Director
  • Christina T. Morrison, Director (Age 48)
  • Kenneth A. Di Pietro, Independent Director (Age 58)
  • Daniel R. Marshak Ph.D., Independent Director (Age 58)

Who owns Invivo Therapeutics stock?

Invivo Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.62%). View Institutional Ownership Trends for Invivo Therapeutics.

Who sold Invivo Therapeutics stock? Who is selling Invivo Therapeutics stock?

Invivo Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Invivo Therapeutics.

How do I buy Invivo Therapeutics stock?

Shares of Invivo Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Invivo Therapeutics' stock price today?

One share of Invivo Therapeutics stock can currently be purchased for approximately $0.47.

How big of a company is Invivo Therapeutics?

Invivo Therapeutics has a market capitalization of $17.82 million. The biotechnology company earns $-23,430,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis. Invivo Therapeutics employs 37 workers across the globe.

How can I contact Invivo Therapeutics?

Invivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-863-5500 or via email at [email protected]


MarketBeat Community Rating for Invivo Therapeutics (NVIV)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  69 (Vote Outperform)
Underperform Votes:  42 (Vote Underperform)
Total Votes:  111
MarketBeat's community ratings are surveys of what our community members think about Invivo Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Invivo Therapeutics (NASDAQ:NVIV) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.00$6.00$6.00$6.00
Price Target Upside: 233.33% upside233.33% upside233.33% upside233.33% upside

Invivo Therapeutics (NASDAQ:NVIV) Consensus Price Target History

Price Target History for Invivo Therapeutics (NASDAQ:NVIV)

Invivo Therapeutics (NASDAQ:NVIV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/31/2017Raymond James FinancialDowngradeOutperform -> Market PerformN/AView Rating Details
7/21/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$23.25N/AView Rating Details
5/12/2016HC WainwrightReiterated RatingBuyN/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Invivo Therapeutics (NASDAQ:NVIV) Earnings History and Estimates Chart

Earnings by Quarter for Invivo Therapeutics (NASDAQ:NVIV)

Invivo Therapeutics (NASDAQ NVIV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2018($0.16)N/AView Earnings Details
10/30/2017Q3 2017($0.22)($0.28)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.21)($0.20)ViewN/AView Earnings Details
5/4/2017Q1 2017($0.22)($0.20)ViewN/AView Earnings Details
3/10/2017Q4 2016($0.20)($0.21)ViewN/AView Earnings Details
11/4/2016Q3($0.20)($0.18)ViewN/AView Earnings Details
8/4/2016Q2($0.22)($0.18)ViewN/AView Earnings Details
5/6/2016Q1 2016($0.26)($0.20)ViewN/AView Earnings Details
3/4/2016Q4 2015($0.22)($0.19)ViewN/AView Earnings Details
11/4/2015Q3 2015($0.20)($0.22)ViewN/AView Earnings Details
8/5/2015Q2 2015($0.18)($0.21)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.11)($0.22)ViewN/AView Earnings Details
3/11/2015Q4 2014($0.24)($0.16)ViewN/AView Earnings Details
11/5/2014Q3 2014($0.24)($0.16)ViewN/AView Earnings Details
8/6/2014Q2 2014($0.24)($0.20)ViewN/AView Earnings Details
5/12/2014Q1 2014($0.32)($0.28)ViewN/AView Earnings Details
3/17/2014($0.08)($0.06)ViewN/AView Earnings Details
11/7/2013Q3 2013($0.28)($0.28)ViewN/AView Earnings Details
8/7/2013Q2 2013($0.28)($0.32)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.32)($0.16)ViewN/AView Earnings Details
3/13/2013Q4 2012($0.24)($0.28)ViewN/AView Earnings Details
11/14/2012Q3 2012($0.24)($0.16)ViewN/AView Earnings Details
8/14/2012Q2 2012($0.24)($0.15)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.08)($0.18)ViewN/AView Earnings Details
3/15/2012Q4 2011($0.16)($0.20)ViewN/AView Earnings Details
11/15/2011Q3 2011($0.16)($0.16)ViewN/AView Earnings Details
8/11/2011Q2 2011($0.12)($0.20)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Invivo Therapeutics (NASDAQ:NVIV) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.81 EPS
Next Year EPS Consensus Estimate: $-0.74 EPS

Dividends

Dividend History for Invivo Therapeutics (NASDAQ:NVIV)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Invivo Therapeutics (NASDAQ NVIV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 12.10%
Insider Trades by Quarter for Invivo Therapeutics (NASDAQ:NVIV)
Insider Trades by Quarter for Invivo Therapeutics (NASDAQ:NVIV)

Invivo Therapeutics (NASDAQ NVIV) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/9/2014Francis ReynoldsMajor ShareholderSell50,000$1.20$60,000.00View SEC Filing  
5/5/2014Francis ReynoldsMajor ShareholderSell37,500$1.87$70,125.00View SEC Filing  
4/30/2014Francis ReynoldsMajor ShareholderSell37,500$1.82$68,250.00View SEC Filing  
4/25/2014Francis ReynoldsMajor ShareholderSell50,000$1.52$76,000.00View SEC Filing  
4/21/2014Francis ReynoldsMajor ShareholderSell50,000$1.57$78,500.00View SEC Filing  
4/14/2014Francis ReynoldsMajor ShareholderSell37,500$1.63$61,125.00View SEC Filing  
4/9/2014Francis ReynoldsMajor ShareholderSell37,500$1.60$60,000.00View SEC Filing  
4/4/2014Francis ReynoldsMajor ShareholderSell25,000$1.71$42,750.00View SEC Filing  
4/2/2014Francis ReynoldsMajor ShareholderSell37,500$1.71$64,125.00View SEC Filing  
3/26/2014Francis ReynoldsMajor ShareholderSell47,900$1.80$86,220.00View SEC Filing  
3/21/2014Francis ReynoldsMajor ShareholderSell39,600$2.15$85,140.00View SEC Filing  
3/17/2014Francis ReynoldsMajor ShareholderSell37,500$2.44$91,500.00View SEC Filing  
3/12/2014Francis ReynoldsMajor ShareholderSell37,500$2.33$87,375.00View SEC Filing  
3/7/2014Francis ReynoldsMajor ShareholderSell25,000$2.44$61,000.00View SEC Filing  
3/5/2014Francis ReynoldsMajor ShareholderSell37,500$2.49$93,375.00View SEC Filing  
2/28/2014Francis ReynoldsMajor ShareholderSell25,000$2.44$61,000.00View SEC Filing  
2/26/2014Francis ReynoldsMajor ShareholderSell37,500$2.28$85,500.00View SEC Filing  
2/21/2014Francis ReynoldsMajor ShareholderSell25,000$2.23$55,750.00View SEC Filing  
2/19/2014Francis ReynoldsMajor ShareholderSell25,000$2.25$56,250.00View SEC Filing  
2/14/2014Francis ReynoldsMajor ShareholderSell25,000$2.24$56,000.00View SEC Filing  
2/12/2014Francis ReynoldsMajor ShareholderSell37,500$2.25$84,375.00View SEC Filing  
2/7/2014Francis ReynoldsMajor ShareholderSell25,000$2.23$55,750.00View SEC Filing  
2/5/2014Francis ReynoldsMajor ShareholderSell37,500$2.21$82,875.00View SEC Filing  
1/31/2014Francis ReynoldsMajor ShareholderSell25,000$2.17$54,250.00View SEC Filing  
1/29/2014Francis ReynoldsMajor ShareholderSell37,500$2.22$83,250.00View SEC Filing  
1/24/2014Francis ReynoldsMajor ShareholderSell25,000$2.25$56,250.00View SEC Filing  
1/21/2014Francis ReynoldsMajor ShareholderSell37,500$2.36$88,500.00View SEC Filing  
1/15/2014Francis ReynoldsMajor ShareholderSell37,500$2.22$83,250.00View SEC Filing  
1/10/2014Francis ReynoldsMajor ShareholderSell48,000$2.41$115,680.00View SEC Filing  
1/6/2014Francis ReynoldsMajor ShareholderSell36,000$2.28$82,080.00View SEC Filing  
12/31/2013Francis ReynoldsMajor ShareholderSell36,000$2.25$81,000.00View SEC Filing  
12/26/2013Francis ReynoldsMajor ShareholderSell36,000$1.99$71,640.00View SEC Filing  
12/20/2013Francis ReynoldsMajor ShareholderSell24,000$1.96$47,040.00View SEC Filing  
12/18/2013Francis ReynoldsMajor ShareholderSell36,000$1.90$68,400.00View SEC Filing  
12/13/2013Francis ReynoldsMajor ShareholderSell24,000$1.80$43,200.00View SEC Filing  
12/11/2013Francis ReynoldsMajor ShareholderSell36,000$1.75$63,000.00View SEC Filing  
12/6/2013Francis ReynoldsMajor ShareholderSell24,000$1.59$38,160.00View SEC Filing  
12/4/2013Francis ReynoldsMajor ShareholderSell36,000$1.90$68,400.00View SEC Filing  
11/22/2013Francis ReynoldsMajor ShareholderSell24,000$1.92$46,080.00View SEC Filing  
11/20/2013Francis ReynoldsMajor ShareholderSell36,000$1.95$70,200.00View SEC Filing  
11/13/2013Francis ReynoldsMajor ShareholderSell36,000$1.14$41,040.00View SEC Filing  
11/8/2013Francis ReynoldsMajor ShareholderSell24,000$1.11$26,640.00View SEC Filing  
11/6/2013Francis ReynoldsMajor ShareholderSell36,000$1.16$41,760.00View SEC Filing  
11/1/2013Francis ReynoldsMajor ShareholderSell24,000$1.16$27,840.00View SEC Filing  
10/30/2013Francis ReynoldsMajor ShareholderSell36,000$1.23$44,280.00View SEC Filing  
10/25/2013Francis ReynoldsMajor ShareholderSell24,000$1.35$32,400.00View SEC Filing  
10/22/2013Francis ReynoldsMajor ShareholderSell24,000$1.40$33,600.00View SEC Filing  
10/18/2013Francis ReynoldsMajor ShareholderSell24,000$1.45$34,800.00View SEC Filing  
10/16/2013Francis ReynoldsMajor ShareholderSell36,000$1.49$53,640.00View SEC Filing  
10/11/2013Francis ReynoldsMajor ShareholderSell24,000$1.51$36,240.00View SEC Filing  
10/9/2013Francis ReynoldsMajor ShareholderSell36,000$1.41$50,760.00View SEC Filing  
10/4/2013Francis ReynoldsMajor ShareholderSell24,000$1.41$33,840.00View SEC Filing  
9/20/2013Francis ReynoldsMajor ShareholderSell24,000$1.37$32,880.00View SEC Filing  
9/18/2013Francis ReynoldsMajor ShareholderSell36,000$1.43$51,480.00View SEC Filing  
9/13/2013Francis ReynoldsMajor ShareholderSell24,000$1.50$36,000.00View SEC Filing  
9/11/2013Francis ReynoldsMajor ShareholderSell24,000$1.72$41,280.00View SEC Filing  
9/6/2013Francis ReynoldsMajor ShareholderSell24,000$1.61$38,640.00View SEC Filing  
9/4/2013Francis ReynoldsMajor ShareholderSell24,000$1.36$32,640.00View SEC Filing  
9/3/2013Sean F MoranCFOBuy20,000$1.02$20,400.00View SEC Filing  
8/30/2013Francis ReynoldsMajor ShareholderSell9,200$1.55$14,260.00View SEC Filing  
8/30/2013Sean F MoranCFOBuy40,000$1.30$52,000.00View SEC Filing  
8/28/2013Francis ReynoldsMajor ShareholderSell12,600$3.24$40,824.00View SEC Filing  
8/23/2013Francis ReynoldsMajor ShareholderSell21,300$4.07$86,691.00View SEC Filing  
8/21/2013Francis ReynoldsCEOSell36,000$4.12$148,320.00View SEC Filing  
8/16/2013Francis ReynoldsCEOSell24,000$4.24$101,760.00View SEC Filing  
8/14/2013Francis ReynoldsCEOSell36,000$4.34$156,240.00View SEC Filing  
8/9/2013Francis ReynoldsCEOSell24,000$4.42$106,080.00View SEC Filing  
8/7/2013Francis ReynoldsCEOSell36,000$4.46$160,560.00View SEC Filing  
8/2/2013Francis ReynoldsCEOSell24,000$4.57$109,680.00View SEC Filing  
7/30/2013Francis ReynoldsCEOSell24,000$5.11$122,640.00View SEC Filing  
7/26/2013Francis ReynoldsCEOSell24,000$5.29$126,960.00View SEC Filing  
7/24/2013Francis ReynoldsCEOSell36,000$5.72$205,920.00View SEC Filing  
7/19/2013Francis ReynoldsCEOSell24,000$5.27$126,480.00View SEC Filing  
7/17/2013Francis ReynoldsCEOSell36,000$5.12$184,320.00View SEC Filing  
7/12/2013Francis ReynoldsCEOSell24,000$4.43$106,320.00View SEC Filing  
7/10/2013Francis ReynoldsCEOSell36,000$3.97$142,920.00View SEC Filing  
7/5/2013Francis ReynoldsCEOSell12,000$4.00$48,000.00View SEC Filing  
7/3/2013Francis ReynoldsCEOSell36,000$4.08$146,880.00View SEC Filing  
6/28/2013Francis ReynoldsCEOSell24,000$4.22$101,280.00View SEC Filing  
6/26/2013Francis ReynoldsCEOSell36,000$3.87$139,320.00View SEC Filing  
6/21/2013Francis ReynoldsCEOSell24,000$3.78$90,720.00View SEC Filing  
6/19/2013Francis ReynoldsCEOSell36,000$3.89$140,040.00View SEC Filing  
6/14/2013Francis ReynoldsCEOSell24,000$3.84$92,160.00View SEC Filing  
6/12/2013Francis ReynoldsCEOSell12,750$4.34$55,335.00View SEC Filing  
6/7/2013Francis ReynoldsCEOSell8,500$4.02$34,170.00View SEC Filing  
6/5/2013Francis ReynoldsCEOSell12,750$3.75$47,812.50View SEC Filing  
6/5/2013Robert LangerMajor ShareholderSell7,500$3.73$27,975.00View SEC Filing  
5/31/2013Francis ReynoldsCEOSell8,500$3.32$28,220.00View SEC Filing  
5/31/2013Robert LangerMajor ShareholderSell7,500$3.31$24,825.00View SEC Filing  
5/29/2013Francis ReynoldsCEOSell8,500$3.13$26,605.00View SEC Filing  
5/28/2013Robert LangerMajor ShareholderSell7,500$2.97$22,275.00View SEC Filing  
5/24/2013Francis ReynoldsCEOSell8,500$2.95$25,075.00View SEC Filing  
5/22/2013Robert LangerMajor ShareholderSell7,500$2.88$21,600.00View SEC Filing  
5/21/2013Francis ReynoldsCEOSell12,750$2.88$36,720.00View SEC Filing  
5/17/2013Francis ReynoldsCEOSell8,500$2.87$24,395.00View SEC Filing  
5/17/2013Robert LangerMajor ShareholderSell7,500$2.85$21,375.00View SEC Filing  
5/15/2013Francis ReynoldsCEOSell12,750$2.89$36,847.50View SEC Filing  
5/14/2013Robert LangerMajor ShareholderSell7,500$2.91$21,825.00View SEC Filing  
5/10/2013Francis ReynoldsCEOSell8,500$2.92$24,820.00View SEC Filing  
5/9/2013Robert LangerMajor ShareholderSell7,500$2.91$21,825.00View SEC Filing  
4/12/2013Francis ReynoldsCEOSell8,500$3.16$26,860.00View SEC Filing  
2/5/2013Francis ReynoldsCEOSell12,750$2.03$25,882.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Invivo Therapeutics (NASDAQ NVIV) News Headlines

Source:
DateHeadline
 Brokerages Anticipate Invivo Therapeutics Holdings Corp (NVIV) Will Announce Earnings of -$0.16 Per Share Brokerages Anticipate Invivo Therapeutics Holdings Corp (NVIV) Will Announce Earnings of -$0.16 Per Share
www.americanbankingnews.com - February 9 at 3:48 PM
Head to Head Survey: PerkinElmer (PKI) & Invivo Therapeutics (NVIV)Head to Head Survey: PerkinElmer (PKI) & Invivo Therapeutics (NVIV)
www.americanbankingnews.com - February 6 at 3:04 AM
Form 8-K INVIVO THERAPEUTICS HOLD For: Feb 02Form 8-K INVIVO THERAPEUTICS HOLD For: Feb 02
www.streetinsider.com - February 5 at 9:48 AM
InVivo Therapeutics Announces Appointment of Richard Toselli, M.D., as President and Chief Executive OfficerInVivo Therapeutics Announces Appointment of Richard Toselli, M.D., as President and Chief Executive Officer
finance.yahoo.com - February 5 at 9:48 AM
Blog Exposure - InVivo Therapeutics Signs Share Repurchase Agreement with Lincoln Park CapitalBlog Exposure - InVivo Therapeutics Signs Share Repurchase Agreement with Lincoln Park Capital
finance.yahoo.com - January 29 at 10:05 AM
Short Interest in Invivo Therapeutics Holdings Corp (NVIV) Decreases By 22.9%Short Interest in Invivo Therapeutics Holdings Corp (NVIV) Decreases By 22.9%
www.americanbankingnews.com - January 29 at 1:40 AM
Invivo Therapeutics (NVIV) Reports Common Share Purchase Agreement for up to $15M with Lincoln Park CapitalInvivo Therapeutics (NVIV) Reports Common Share Purchase Agreement for up to $15M with Lincoln Park Capital
www.streetinsider.com - January 27 at 10:10 AM
BRIEF-Invivo Therapeutics Announces Purchase Agreement For Up To $15 Mln With Lincoln Park CapitalBRIEF-Invivo Therapeutics Announces Purchase Agreement For Up To $15 Mln With Lincoln Park Capital
www.reuters.com - January 26 at 9:50 AM
InVivo Therapeutics Announces Purchase Agreement for up to $15 Million with Lincoln Park CapitalInVivo Therapeutics Announces Purchase Agreement for up to $15 Million with Lincoln Park Capital
finance.yahoo.com - January 26 at 9:50 AM
Head to Head Analysis: Invivo Therapeutics (NVIV) & Hologic (HOLX)Head to Head Analysis: Invivo Therapeutics (NVIV) & Hologic (HOLX)
www.americanbankingnews.com - January 7 at 11:26 PM
-$0.16 EPS Expected for Invivo Therapeutics Holdings Corp (NVIV) This Quarter-$0.16 EPS Expected for Invivo Therapeutics Holdings Corp (NVIV) This Quarter
www.americanbankingnews.com - January 6 at 1:34 PM
Invivo Therapeutics (NVIV) & IRIDEX (IRIX) Head-To-Head ReviewInvivo Therapeutics (NVIV) & IRIDEX (IRIX) Head-To-Head Review
www.americanbankingnews.com - January 6 at 9:46 AM
Analyzing LeMaitre Vascular (LMAT) & Invivo Therapeutics (NVIV)Analyzing LeMaitre Vascular (LMAT) & Invivo Therapeutics (NVIV)
www.americanbankingnews.com - January 5 at 5:04 AM
InVivo Therapeutics Announces Latest Results from INSPIRE and Provides Update on Proposed Clinical Path Forward - Business Wire (press release)InVivo Therapeutics Announces Latest Results from INSPIRE and Provides Update on Proposed Clinical Path Forward - Business Wire (press release)
www.businesswire.com - January 3 at 9:36 AM
InVivo Therapeutics Announces Latest Results from INSPIRE and Provides Update on Proposed Clinical Path ForwardInVivo Therapeutics Announces Latest Results from INSPIRE and Provides Update on Proposed Clinical Path Forward
finance.yahoo.com - January 3 at 9:36 AM
Invivo Therapeutics (NVIV) versus Its Rivals Financial ReviewInvivo Therapeutics (NVIV) versus Its Rivals Financial Review
www.americanbankingnews.com - December 20 at 5:18 AM
BRIEF-InVivo Therapeutics Announces Executive Management And Board ChangesBRIEF-InVivo Therapeutics Announces Executive Management And Board Changes
www.reuters.com - December 18 at 4:32 PM
Invivo Therapeutics (NVIV) Appoints Richard Toselli, MD as CEO Following Resignation for Mark Perrin from CEO and ... - StreetInsider.comInvivo Therapeutics (NVIV) Appoints Richard Toselli, MD as CEO Following Resignation for Mark Perrin from CEO and ... - StreetInsider.com
www.streetinsider.com - December 18 at 10:45 AM
InVivo Therapeutics Announces Executive Management and Board ChangesInVivo Therapeutics Announces Executive Management and Board Changes
finance.yahoo.com - December 18 at 10:45 AM
Analyzing Invivo Therapeutics (NVIV) and Its PeersAnalyzing Invivo Therapeutics (NVIV) and Its Peers
www.americanbankingnews.com - December 18 at 1:34 AM
Invivo Therapeutics (NVIV) versus Its Peers Critical SurveyInvivo Therapeutics (NVIV) versus Its Peers Critical Survey
www.americanbankingnews.com - December 16 at 9:24 PM
Invivo Therapeutics (NVIV) versus The Competition Financial ComparisonInvivo Therapeutics (NVIV) versus The Competition Financial Comparison
www.americanbankingnews.com - December 16 at 1:30 AM
Contrasting Invivo Therapeutics (NVIV) & Its RivalsContrasting Invivo Therapeutics (NVIV) & Its Rivals
www.americanbankingnews.com - December 12 at 9:18 AM
InVivo Therapeutics (NVIV) vs. Its Rivals Critical SurveyInVivo Therapeutics (NVIV) vs. Its Rivals Critical Survey
www.americanbankingnews.com - December 8 at 3:30 PM
Head to Head Analysis: InVivo Therapeutics (NVIV) vs. Its PeersHead to Head Analysis: InVivo Therapeutics (NVIV) vs. Its Peers
www.americanbankingnews.com - December 8 at 3:30 PM
InVivo Therapeutics Holdings Corp. (NVIV) Expected to Post Earnings of -$0.16 Per ShareInVivo Therapeutics Holdings Corp. (NVIV) Expected to Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - December 3 at 8:14 AM
InVivo Therapeutics (NVIV) versus Its Competitors Financial SurveyInVivo Therapeutics (NVIV) versus Its Competitors Financial Survey
www.americanbankingnews.com - December 2 at 11:30 PM
Brokerages Anticipate InVivo Therapeutics Holdings Corp. (NVIV) to Post ($0.16) EPSBrokerages Anticipate InVivo Therapeutics Holdings Corp. (NVIV) to Post ($0.16) EPS
www.americanbankingnews.com - December 1 at 7:30 PM
Zacks: Analysts Expect InVivo Therapeutics Holdings Corp. (NVIV) to Announce -$0.16 Earnings Per ShareZacks: Analysts Expect InVivo Therapeutics Holdings Corp. (NVIV) to Announce -$0.16 Earnings Per Share
www.americanbankingnews.com - November 14 at 11:22 PM
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsINVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - May 25 at 8:02 AM
InVivo Therapeutics Announces Notice of Allowance for Patent Covering Methods of Treating Spinal Cord Injuries ... - Business Wire (press release)InVivo Therapeutics Announces Notice of Allowance for Patent Covering Methods of Treating Spinal Cord Injuries ... - Business Wire (press release)
www.businesswire.com - May 18 at 3:16 PM
Analysts Anticipate 22% Upside For EQWSAnalysts Anticipate 22% Upside For EQWS
www.thestreet.com - May 13 at 3:28 PM
InVivo Therapeutics Announces Hospital of the University of Pennsylvania as New Site for INSPIRE Study - Business Wire (press release)InVivo Therapeutics Announces Hospital of the University of Pennsylvania as New Site for INSPIRE Study - Business Wire (press release)
www.businesswire.com - May 11 at 3:28 PM
Earnings Reported After The Bell May 6Earnings Reported After The Bell May 6
www.nasdaq.com - May 9 at 3:26 PM
BRIEF-Invivo Therapeutics Holdings Q1 loss per share $0.24 - ReutersBRIEF-Invivo Therapeutics Holdings Q1 loss per share $0.24 - Reuters
www.reuters.com - May 6 at 8:36 PM
InVivo Therapeutics Reports 2016 First Quarter Financial Results and Business Update - Business Wire (press release)InVivo Therapeutics Reports 2016 First Quarter Financial Results and Business Update - Business Wire (press release)
www.businesswire.com - May 6 at 8:36 PM
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 10-Q, Quarterly ReportINVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - May 6 at 4:31 PM
InVivo Therapeutics Announces Symposium at 84th American Association for Neurological Surgeons Annual Scientific ... - Business Wire (press release)InVivo Therapeutics Announces Symposium at 84th American Association for Neurological Surgeons Annual Scientific ... - Business Wire (press release)
www.businesswire.com - May 2 at 3:27 PM
Invivo Therapeutics (NVIV) Announces Sixth-Implanted Patient in INSPIRE Study Improved to Incomplete AIS B Spinal ... - StreetInsider.comInvivo Therapeutics (NVIV) Announces Sixth-Implanted Patient in INSPIRE Study Improved to Incomplete AIS B Spinal ... - StreetInsider.com
www.streetinsider.com - April 26 at 8:37 PM
InVivo Therapeutics Reports Conversion of a Fourth Patient Implanted with the Neuro-Spinal Scaffold™ in the INSPIRE ... - Business Wire (press release)InVivo Therapeutics Reports Conversion of a Fourth Patient Implanted with the Neuro-Spinal Scaffold™ in the INSPIRE ... - Business Wire (press release)
www.businesswire.com - April 26 at 3:32 PM
Pre-Open Stock Movers 04/26: (KN) (TCS) (PETX) Higher; (CPRX) (SRPT) (WHR) Lower (more...)Pre-Open Stock Movers 04/26: (KN) (TCS) (PETX) Higher; (CPRX) (SRPT) (WHR) Lower (more...)
www.streetinsider.com - April 26 at 3:32 PM
Oversold Conditions For InVivo Therapeutics Holdings (NVIV)Oversold Conditions For InVivo Therapeutics Holdings (NVIV)
www.thestreet.com - April 25 at 3:32 PM
InVivo Therapeutics to Present at Committee Roundtable on Biomedical Engineering Materials and Applications - Business Wire (press release)InVivo Therapeutics to Present at Committee Roundtable on Biomedical Engineering Materials and Applications - Business Wire (press release)
www.businesswire.com - April 20 at 3:28 PM
InVivo Therapeutics Expresses Condolences on Death of Eighth Patient Enrolled in INSPIRE Study - Business Wire (press release)InVivo Therapeutics Expresses Condolences on Death of Eighth Patient Enrolled in INSPIRE Study - Business Wire (press release)
www.businesswire.com - April 19 at 3:30 PM
BRIEF-Invivo Therapeutics says CEO Mark Perrins total compensation for 2015 was $1.9 mln - ReutersBRIEF-Invivo Therapeutics says CEO Mark Perrin's total compensation for 2015 was $1.9 mln - Reuters
www.reuters.com - April 12 at 8:23 PM
BRIEF-Invivo Therapeutics says CEO Mark Perrins total compensation for 2015 was $1.9 mlnBRIEF-Invivo Therapeutics says CEO Mark Perrin's total compensation for 2015 was $1.9 mln
www.reuters.com - April 12 at 8:23 PM
InVivo Therapeutics Announces John A. McCarthy, Jr. to Not Stand for Re-election - Business Wire (press release)InVivo Therapeutics Announces John A. McCarthy, Jr. to Not Stand for Re-election - Business Wire (press release)
www.businesswire.com - April 12 at 3:18 PM
InVivo Therapeutics Announces John A. McCarthy, Jr. To Not Stand For Re-electionInVivo Therapeutics Announces John A. McCarthy, Jr. To Not Stand For Re-election
www.thestreet.com - April 12 at 3:18 PM
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Change in Directors or Principal OfficersINVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - April 12 at 8:01 AM
InVivo Therapeutics Announces University of Virginia Health System as New Site for INSPIRE Study - Business Wire (press release)InVivo Therapeutics Announces University of Virginia Health System as New Site for INSPIRE Study - Business Wire (press release)
www.businesswire.com - April 5 at 3:17 PM

SEC Filings

Invivo Therapeutics (NASDAQ:NVIV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Invivo Therapeutics (NASDAQ:NVIV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Invivo Therapeutics (NASDAQ NVIV) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.